

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: **Laura Gillim-Ross *et al.***

Serial No.: **10/699,936**

Group No.: **1648**

Filed: **11/03/2003**

Examiner: **Mosher, M.E.**

Entitled:

**COMPOSITIONS AND METHODS FOR DETECTING
SEVERE ACUTE RESPIRATORY SYNDROME
CORONAVIRUS**

INFORMATION DISCLOSURE STATEMENT

MS Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: June 29, 2005

By: _____

Cliff Cannon-Cin
Cliff Cannon-Cin

Dear Madam:

The citations listed below, copies of 60 non-patent references attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following patents and other printed publications are referred to in the body of the Specification:

- U.S. Patent No. 4,244,946 to Rivier *et al.*, "Water-soluble peptides affecting gonadal function (1981);
- U.S. Patent No. 4,946,778 to Ladner *et al.*, "Single polypeptide chain binding molecules (1990);
- U.S. Patent No. 5,270,163 to Gold *et al.*, "Methods for identifying nucleic acid ligands (1993);

- U.S. Patent No. 5,545,806 to Lonberg *et al.*, "Transgenic non-human animals for producing heterologous antibodies," (1996);
- U.S. Patent No. 5,569,825 to Lonberg *et al.*, "Transgenic non-human animals capable of producing heterologous antibodies of various isotypes," (1996);
- U.S. Patent No. 5,625,126 to Lonberg *et al.*, "Transgenic non-human animals for producing heterologous antibodies (1997);
- U.S. Patent No. 5,760,029 to Jadhav *et al.*, "Spirocycle integrin inhibitors," (1998);
- U.S. Patent No. 6,252,043 to Hession *et al.*, "Vascular cell adhesion molecule (VCAM) polypeptides," (2001);
- U.S. Patent No. 6,376,172 to Scholl *et al.*, "Mixed cell diagnostic systems," (2002);
- U.S. Patent No. 6,472,206 to Scholl *et al.*, "In situ growth, freezing and testing of cultured cells," (2002);
- U.S. Patent No. 6,610,474 to Huang, "Cells for detection of influenza and parainfluenza viruses," (2003);
- EP Patent Application Publication No. 0 140 308 of Inouye *et al.*, "Regulation of gene expression by employing translational inhibition utilizing mRNA interfering complementary RNA," (1985);
- Benbacer *et al.* (1997) "Interspecies aminopeptidase-*N* chimerase reveal species-specific receptor recognition by canine coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus," J Virol, 71:734-737;
- Blondelle *et al.* (1995) "Soluble combinatorial libraries of organic, peptidomimetic and peptide diversities," Trends Anal Chem, 14:83-92;
- Chaloner-Larsson *et al.* "Establishment and maintenance of a persistent infection of L132 cells by human coronavirus strain 229E," (1981) Arch Virol, 69:117-129;
- Cole *et al.*, (1985) "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp 77-96;

- Compton *et al.* (1982) "Coronavirus species specificity: Murine coronavirus binds to a mouse-specific epitope on its carcinoembryonic antigen-related receptor glycoprotein," J Virol, 66:7420-7428;
- Cote *et al.* (1983) "Generation of human monoclonal antibodies reactive with cellular antigens," Proc Natl Acad Sci USA, 80:2026-2030;
- de Kruif *et al.* (1996) "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes," FEBS Lett, 399:232-236;
- Delmas *et al.* (1992) "Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV," Nature, 357:417-420;
- Ding *et al.* (1995) "Synthesis and biological activity of oligosaccharide libraries," Adv Exp Med Biol, 376:261-269;
- Drosten *et al.* (2003) "Identification of a novel coronavirus in patients with severe acute respiratory syndrome," N Engl J Med, 348:1967-1976;
- Dveksler *et al.* (1991) "Cloning of the mouse hepatitis virus (MHV) receptor: Expression in human and hamster cell lines confers susceptibility to MHV," J Virol, 65:6881-6891;
- Dveksler *et al.* (1995) "Mouse hepatitis virus receptor activities of an MHVR/MPH chimera and MHVR mutants lacking N-linked glycosylation of the N-terminal domain," J Virol, 69:543-546;
- Dveksler *et al.* (1996) "Expression of the recombinant anchorless N-terminal domain of mouse hepatitis virus (MHV) receptor makes hamster or human cells susceptible to MHV infection," J Virol, 70:4142-4145;
- Ecker and Crook (1995) "Combinatorial drug discovery: Which methods will produce the greatest value?" Bio/Technology 13:351-360;
- Fields and Noble (1990) "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids," Intl Peptide Protein Res, 35:161-214;
- Fouchier *et al.* (2003) "Koch's postulates fulfilled for SARS virus," Nature, 423:240;
- Gleaves *et al.* (1992) "Detection of human cytomegalovirus in clinical specimens by centrifugation culture with a nonhuman cell line," J Clin Microbiol 30:1045-8;

- Gordon *et al.* (1994) "Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions," *J Med Chem*, 37:1385-1401;
- Hambor *et al.* (1988) "Functional consequences of anti-sense RNA-mediated inhibition of CD8 surface expression in a human T cell clone," *J Exp Med*, 168:1237-1245;
- Holmes and Lai (1996) "Coronaviridae: The Viruses and Their Replication," in *Fields Virology*, Third Edition, Lippincott-Raven, pp. 1075-1093;
- Holmes *et al.* (2001) "Coronaviruses," in *Fields Virology*, Fourth Edition, Lippincott Williams & Wilkins, Chapter 36, pp. 1187-1203;
- Huse *et al.* (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," *Science*, 246:1275-1281;
- Karaoglu *et al.* (1995) "Functional characterization of Ost3p. Loss of the 34-kD subunit of the *Saccharomyces cerevisiae* oligosaccharyltransferase results in biased underglycosylation of acceptor substrates," *J Cell Biol*, 130:567-577;
- Köhler and Milstein (1975) "Continuous cultures of fused cells secreting antibody of predefined specificity," *Nature*, 256:495-497;
- Koivunen *et al.* (1994) "Isolation of a highly specific ligand for the $\alpha_5\beta_1$ integrin from a phage display library," *J Cell Biol*, 124: 373-380;
- Kolb *et al.* (1997) "Identification of residues critical for the human coronavirus 229E receptor function of human aminopeptidase N," *J Gen Virol*, 78:2795-2802;
- Kontoyiannis *et al.* (2003) "Aminopeptidase N inhibitors and SARS," *Lancet*, 361:1558;
- Kozbor *et al.* (1983) "The production of monoclonal antibodies from human lymphocytes," *Immunol Today*, 4:72;
- Ksiazek *et al.* (2003) "A novel coronavirus associated with severe acute respiratory syndrome," *N Engl J Med*, 348:1953-1966;
- Kuiken *et al.* (2003) "Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome," *Lancet*, 362:263-270;
- Liang *et al.* (1996) "Parallel synthesis and screening of a solid phase carbohydrate library," *Science*, 274:1520-1522;

- Look *et al.* (1989) "Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N," J Clin Invest, 83:1299-1307;
- Markus-Sekura (1988) "Techniques for using antisense oligodeoxyribonucleotides to study gene expression," Anal Biochem, 172:289-295;
- Marra *et al.* (2003) "The genome sequence of the SARS-associated coronavirus," Science, 300:1399-1404;
- Meienhofer, (1973) "Peptide synthesis: A review of the solid-phase method," in *Hormonal Proteins and Peptides*, Vol. II, Chapter 3, Academic Press (title and copyright pages only);
- Murphy and Chanock, (2001) "Immunization against viral diseases" in *Fields Virology*, Fourth Edition, Knipe and Howley, Lippincott Williams & Wilkins, Chapter 16, pp. 435-467;
- Nakabayashi *et al.* (1982) "Growth of human hepatoma cell lines with differentiated function in chemically defined medium," Cancer Res, 42: 3858-3863;
- Nakabayashi *et al.* (1984) "Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium," Gann, 75: 151-158 (abstract only);
- Nakabayashi *et al.* (1985) "Hormonal control of α -fetoprotein secretion in human hepatoma cell lines proliferating in chemically defined medium," Cancer Res. 45:6379-6383;
- Palache *et al.* (1997) "Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs," J Infect Dis, 176(Suppl 1):S20-S23;
- Peiris *et al.* (2003) "Coronavirus as a possible cause of severe acute respiratory syndrome," Lancet, 361:1319-1325;
- Poon *et al.* (2003) "Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS)," Clin Chem, 49:953-955;
- Poutanen *et al.* (2003) "Identification of severe acute respiratory syndrome in Canada," N Engl J Med, 348:1995-2005;

- Rota *et al.* (2003) "Characterization of a novel coronavirus associated with severe acute respiratory syndrome," *Science*, 300:1394-1399;
- Sawicki and Sawicki (1995) "Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands," *Adv Exp Med Biol*, 380:499-506;
- Sawicki and Sawicki (1998) "A new model for coronavirus transcription," *Adv Exp Biol*, 440:215-219;
- Sawicki *et al.* (2001) "The RNA structures engaged in replication and transcription of the A59 strain of mouse hepatitis virus," *J Gen Virol*, 385-96;
- Snijder *et al.* (2003) "Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage," *J Mol Biol*, 331:991-1004;
- Thiel *et al.* (2003) "Mechanisms and enzymes involved in SARS coronavirus genome expression," *J Gen Virol*, 84:2305-2315;
- Tresnan *et al.* (1996) "Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I," *J Virol*, 70:8669-8674;
- Ward *et al.* (1989) "Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*," *Nature*, 341:544-546;
- Wentworth *et al.* (2001) "Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): Influence of N-Linked glycosylation," *J Virol*, 75:9741-9752;
- Williams *et al.* (1990) "Purification of the 110-kilodalton glycoprotein receptor for mouse hepatitis virus (MHV)-A59 from mouse liver and identification of a nonfunctional, homologous protein in MHV-resistant SJL/J mice," *J Virol*, 64:3817-3823;
- Williams *et al.* (1991) "Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins," *Proc Natl Acad Sci USA*, 88:5533-5536;
- Winter and Harris (1993) "Humanized antibodies," *Immunol Today*, 14:243-246;
- Yeager *et al.* (1992) "Human aminopeptidase N is a receptor for human coronavirus 229E," *Nature*, 357:420-422 (abstract only);

- York *et al.* (1996) "The structures of arabinoxyloglucans produced by solanaceous plants," Carb Res, 285:99-128;
- Yount *et al.* (2003) "Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus," Proc Natl Acad Sci USA, 100:12995-13000;
- Yu *et al.* (2003) "Putative hAPN receptor binding sites in SARS CoV spike protein," Acta Pharmacol Sin, 24:481-488; and
- Zeng *et al.* (2003) "The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39)," Exp Biol Med, 228:866-73.


This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: June 29, 2005



Christine A. Lekutis
Registration No. 51,934

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500

FORM PTO-1449 (Modified)				U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: DHI-07986		Serial No.: 10/699,936	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR § 1.98(b))						Applicant: Laura Gillim-Ross et al.			
						Filing or 371(c) Date: 11/03/2003		Group Art Unit: 1648	
U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date		
	1	4,244,946	13 Jan 1981	Rivier et al.	424	177	11 Jun 1979		
	2	4,949,778	7 Aug 1990	Ladner et al.	435	69.6	19 Jan 1989		
	3	5,270,163	14 Dec 1993	Gold et al.	435	6	17 Aug 1992		
	4	5,545,806	13 Aug 1996	Lonberg et al.	800	2	16 Dec 1992		
	5	5,569,825	29 Oct 1996	Lonberg et al.	800	2	17 Dec 1991		
	6	5,625,126	29 Apr 1997	Lonberg et al.	800	2	7 Dec 1994		
	7	5,760,029	2 Jun 1998	Jadhav et al.	514	211	13 Mar 1997		
	8	6,252,043	26 Jun 2001	Hession et al.	530	350	22 Sep 1994		
	9	6,376,172	23 Apr 2002	Scholl et al.	435	5	14 Sep 2000		
	10	6,472,206	29 Oct 2002	Scholl et al.	435	325	28 Apr 2000		
	11	6,610,474	26 Aug 2003	Huang	435	5	25 Apr 2002		
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS									
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation		
							Yes	No	
	12	EP 0 140 308	8 May 1985	EPO					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)									
	13	Benbacer et al. (1997) "Interspecies aminopeptidase-N chimera reveal species-specific receptor recognition by canine coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus," J Virol, 71:734-737							
	14	Blondelle et al. (1995) "Soluble combinatorial libraries of organic, peptidomimetic and peptide diversities," Trends Anal Chem, 14:83-92							
	15	Chaloner-Larsson et al. "Establishment and maintenance of a persistent infection of L132 cells by human coronavirus strain 229E," (1981) Arch Virol, 69:117-129							
	16	Cole et al., (1985) "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp 77-96							
	17	Compton et al. (1982) "Coronavirus species specificity: Murine coronavirus binds to a mouse-specific epitope on its carcinoembryonic antigen-related receptor glycoprotein," J Virol, 66:7420-7428							
	18	Cote et al. (1983) "Generation of human monoclonal antibodies reactive with cellular antigens," Proc Natl Acad Sci USA, 80:2026-2030							
	19	de Kruif et al. (1996) "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes," FEBS Lett, 399:232-236							
	20	Delmas et al. (1992) "Aminopeptidase N is a major receptor for the enteropathogenic coronavirus TGEV," Nature, 357:417-420							
	21	Ding et al. (1995) "Synthesis and biological activity of oligosaccharide libraries," Adv Exp Med Biol, 376:261-269							
	22	Drosten et al. (2003) "Identification of a novel coronavirus in patients with severe acute respiratory syndrome," N Engl J Med, 348:1967-1976							
	23	Dveksler et al. (1991) "Cloning of the mouse hepatitis virus (MHV) receptor: Expression in human and hamster cell lines confers susceptibility to MHV," J Virol, 65:6881-6891							
	24	Dveksler et al. (1995) "Mouse hepatitis virus receptor activities of an MHVR/MPH chimera and MHVR mutants lacking N-linked glycosylation of the N-terminal domain," J Virol, 69:543-546							
	25	Dveksler et al. (1996) "Expression of the recombinant anchorless N-terminal domain of mouse hepatitis virus (MHV) receptor makes hamster of human cells susceptible to MHV infection," J Virol, 70:4142-4145							
Examiner:					Date Considered:				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: DHI-07986	Serial No.: 10/699,936
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: Laura Gillim-Ross et al.	
				Filing or 371(c) Date: 11/03/2003	Group Art Unit: 1648
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
	26	Ecker and Crook (1995) "Combinatorial drug discovery: Which methods will produce the greatest value?" <i>Bio/Technology</i> 13:351-360			
	27	Fields and Noble (1990) "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids," <i>Intl Peptide Protein Res</i> , 35:161-214			
	28	Fouchier <i>et al.</i> (2003) "Koch's postulates fulfilled for SARS virus," <i>Nature</i> , 423:240			
	29	Gleaves <i>et al.</i> (1992) "Detection of human cytomegalovirus in clinical specimens by centrifugation culture with a nonhuman cell line," <i>J Clin Microbiol</i> 30:1045-8			
	30	Gordon <i>et al.</i> (1994) "Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions," <i>J Med Chem</i> , 37:1385-1401			
	31	Hambor <i>et al.</i> (1988) "Functional consequences of anti-sense RNA-mediated inhibition of CD8 surface expression in a human T cell clone," <i>J Exp Med</i> , 168:1237-1245			
	32	Holmes and Lai (1996) "Coronaviridae: The Viruses and Their Replication," in <i>Fields Virology</i> , Third Edition, Lippincott-Raven, pp. 1075-1093			
	33	Holmes <i>et al.</i> (2001) "Coronaviruses," in <i>Fields Virology</i> , Fourth Edition, Lippincott Williams & Wilkins, Chapter 36, pp. 1187-1203			
	34	Huse <i>et al.</i> (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> , 246:1275-1281			
	35	Karaoglu <i>et al.</i> (1995) "Functional characterization of Ost3p. Loss of the 34-kD subunit of the <i>Saccharomyces cerevisiae</i> oligosaccharyltransferase results in biased underglycosylation of acceptor substrates," <i>J Cell Biol</i> , 130:567-577			
	36	Köhler and Milstein (1975) "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 256:495-497			
	37	Koivunen <i>et al.</i> (1994) "Isolation of a highly specific ligand for the $\alpha\beta_1$ integrin from a phage display library," <i>J Cell Biol</i> , 124: 373-380			
	38	Kolb <i>et al.</i> (1997) "Identification of residues critical for the human coronavirus 229E receptor function of human aminopeptidase N," <i>J Gen Virol</i> , 78:2795-2802			
	39	Kontoyiannis <i>et al.</i> (2003) "Aminopeptidase N inhibitors and SARS," <i>Lancet</i> , 361:1558			
	40	Kozbor <i>et al.</i> (1983) "The production of monoclonal antibodies from human lymphocytes," <i>Immunol Today</i> , 4:72			
	41	Ksiazek <i>et al.</i> (2003) "A novel coronavirus associated with severe acute respiratory syndrome," <i>N Engl J Med</i> , 348:1953-1966			
	42	Kuiken <i>et al.</i> (2003) "Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome," <i>Lancet</i> , 362:263-270			
	43	Liang <i>et al.</i> (1996) "Parallel synthesis and screening of a solid phase carbohydrate library," <i>Science</i> , 274:1520-1522			
	44	Look <i>et al.</i> (1989) "Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N," <i>J Clin Invest</i> , 83:1299-1307			
	45	Markus-Sekura (1988) "Techniques for using antisense oligodeoxyribonucleotides to study gene expression," <i>Anal Biochem</i> , 172:289-295			
	46	Marra <i>et al.</i> (2003) "The genome sequence of the SARS-associated coronavirus," <i>Science</i> , 300:1399-1404			
	47	Meienhofer, (1973) "Peptide synthesis: A review of the solid-phase method," in <i>Hormonal Proteins and Peptides</i> , Vol. II, Chapter 3, Academic Press (title and copyright pages only)			
	48	Murphy and Chanock, (2001) "Immunization against viral diseases" in <i>Fields Virology</i> , Fourth Edition, Knipe and Howley, Lippincott Williams & Wilkins, Chapter 16, pp. 435-467			
	49	Nakabayashi <i>et al.</i> (1982) "Growth of human hepatoma cell lines with differentiated function in chemically defined medium," <i>Cancer Res</i> , 42: 3858-3863			
	50	Nakabayashi <i>et al.</i> (1984) "Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium," <i>Gann</i> , 75: 151-158 (abstract only)			
	51	Nakabayashi <i>et al.</i> (1985) "Hormonal control of α -fetoprotein secretion in human hepatoma cell lines proliferating in chemically defined medium," <i>Cancer Res</i> . 45:6379-6383			
	52	Palache <i>et al.</i> (1997) "Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs," <i>J Infect Dis</i> , 176(Suppl 1):S20-S23			
	53	Peiris <i>et al.</i> (2003) "Coronavirus as a possible cause of severe acute respiratory syndrome," <i>Lancet</i> , 361:1319-1325			
	54	Poon <i>et al.</i> (2003) "Rapid diagnosis of a coronavirus associated with severe acute respiratory syndrome (SARS)," <i>Clin Chem</i> , 49:953-955			
	55	Poutanen <i>et al.</i> (2003) "Identification of severe acute respiratory syndrome in Canada," <i>N Engl J Med</i> , 348:1995-2005			
Examiner:			Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: DHI-07986	Serial No.: 10/699,936
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: Laura Gillim-Ross et al.	
				Filing or 371(c) Date: 11/03/2003	Group Art Unit: 1648
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
56	Rota <i>et al.</i> (2003)	"Characterization of a novel coronavirus associated with severe acute respiratory syndrome," Science, 300:1394-1399			
57	Sawicki and Sawicki (1995)	"Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands," Adv Exp Med Biol, 380:499-506			
58	Sawicki and Sawicki (1998)	"A new model for coronavirus transcription," Adv Exp Biol, 440:215-219			
59	Sawicki <i>et al.</i> (2001)	"The RNA structures engaged in replication and transcription of the A59 strain of mouse hepatitis virus," J Gen Virol, 385-96			
60	Snijder <i>et al.</i> (2003)	"Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage," J Mol Biol, 331:991-1004			
61	Thiel <i>et al.</i> (2003)	"Mechanisms and enzymes involved in SARS coronavirus genome expression," J Gen Virol, 84:2305-2315			
62	Tresnan <i>et al.</i> (1996)	"Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup 1," J Virol, 70:8669-8674			
63	Ward <i>et al.</i> (1989)	"Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," Nature, 341:544-546			
64	Wentworth <i>et al.</i> (2001)	"Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): Influence of N-Linked glycosylation," J Virol, 75:9741-9752			
65	Williams <i>et al.</i> (1990)	"Purification of the 110-kilodalton glycoprotein receptor for mouse hepatitis virus (MHV)-A59 from mouse liver and identification of a nonfunctional, homologous protein in MHV-resistant SJL/J mice," J Virol, 64:3817-3823			
66	Williams <i>et al.</i> (1991)	"Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins," Proc Natl Acad Sci USA, 88:5533-5536			
67	Winter and Harris (1993)	"Humanized antibodies," Immunol Today, 14:243-246			
68	Yeager <i>et al.</i> (1992)	"Human aminopeptidase N is a receptor for human coronavirus 229E," Nature, 357:420-422 (abstract only)			
69	York <i>et al.</i> (1996)	"The structures of arabinoxyloglucans produced by solanaceous plants," Carb Res, 285:99-128			
70	Yount <i>et al.</i> (2003)	"Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus," Proc Natl Acad Sci USA, 100:12995-13000			
71	Yu <i>et al.</i> (2003)	"Putative hAPN receptor binding sites in SARS CoV spike protein," Acta Pharmacol Sin, 24:481-488			
72	Zeng <i>et al.</i> (2003)	"The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39)," Exp Biol Med, 228:866-73			
73					
74					
75					
76					
77					
78					
79					
80					
81					
82					
83					
84					
85					
Examiner:			Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					